Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Catalent, Novo Nordisk and FTC
Consumer groups ask FTC to block Novo Holdings-Catalent deal
U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk , from acquiring contract drug manufacturer Catalent ,
Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings
The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in development of cell and gene therapies.
Consumer, labor groups urge FTC to block Catalent sale to Novo Nordisk - report
Financial groups and labor unions urge FTC to block Nordisk Foundation's acquisition of Catalent, citing concerns about competition and gene
4d
on MSN
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
4d
on MSN
Is Novo Nordisk A/S (NVO) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
FiercePharma
2d
EU drug reviewers back Novo Nordisk’s FDA-rejected hemophilia drug, snub PTC’s Translarna again
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
4d
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...
13d
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
1d
Novo Nordisk A/S (NYSE:NVO) Shares Down 0.4% on Analyst Downgrade
Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price fell 0.4% during mid-day trading on Friday after BMO Capital Markets lowered their price target on the stock from $160.00 to $156.00. BMO ...
3d
Behind the Scenes of Novo Nordisk's Latest Options Trends
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Newser on MSN
4d
Novo Nordisk's Insulin Change Attracts Critics
A s a teen, Lecritia Roberts injected herself with insulin using a glass vial and a syringe to manage her type 1 diabetes, ...
11d
Novo Nordisk: Mounting Challenges
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
2d
Novo Nordisk: CHMP Recommends Approval Of Alhemo - Quick Facts
Novo Nordisk announced the European Medicines Agency's CHMP has adopted a positive opinion, recommending approval of Alhemo as the ...
2d
on MSN
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Ozempic
Catalent
Wegovy
New Jersey
Ardena
Feedback